Translate
Subscribe to Blog via Email
Ronny Allan
Diagnosing Neuroendocrine Neoplasms (NENs).
It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can sometimes be difficult to see. Plus, many patients present with relatively routine day to day symptoms suggesting a myriad of day-to-day illnesses seen daily in every GP/PCP practice.
But conversely, many are found incidentally while checking for something else, or in reaction to a visit to the ER/A&E or as a referral by primary care physicians for further checks at secondary facilities. A few examples:
1. Most appendiceal NETs are found when patients present with pain in the right lower quadrant i.e. symptoms of appendicitis. The resulting appendectomy will find the tumour. However, it’s true to say that most appendectomies will be connected to appendicitis with no NET involvement. Nonetheless, the number of NETs discovered this way is significant, but most will be removed with curative intent. They rarely metastasise at the lower grades.
2. Many Gastric NETs are found when investigating symptoms of heartburn/acid reflux issues. They are almost always found by simple endoscopy checks using cameras and needle biopsies. They rarely metastasise at the lower grades.
3. Many Rectal NETs are being found via colonoscopies when investigating symptoms of abdominal issues plus (e.g.) as a follow up to abnormal tests on faecal immunochemical test (FIT) as part of regular government cancer screening initiatives. Like appendiceal NETs, most of these will be removed with curative intent. They rarely metastasise at the lower grades.
4. More and more small intestine NETs are being found via extended colonoscopies (based on the common location of the terminal ileum) plus as a follow up to abnormal tests on faecal immunochemical test (FIT) as part of regular government cancer screening initiatives.
5. More and more pancreatic NETs are being found a combination of endoscopy examinations and conventional imaging.
6. Diagnoses of Lung NETs can be triggered by simple x-rays checking for things such as chest infections.
7. Often, doctors move straight to imaging where abnormalities can be spotted which warrants further and deeper investigation.
Most of the above can also be applied to Neuroendocrine Carcinomas (NECs), a poorly differentiated type of NEN.
Despite what you see in patient groups and statistics pushed out by certain organisations, most NETs are localised (i.e. low stage) and grade 1. These statistics can be seen in the SEER US NET study published in 2017 (based on data up to 2012) – this document can be found in my “Not as rare as you think” blog post here. When you consider the game changers below, this should hopefully confirm/improve this situation when new statistics come out in this new era of better imaging and earlier diagnoses. An update to the above SEER dataset is due sometime in 2023.
Imaging is a game changer
As we progress, so does science. Consequently, imaging is playing a part in finding many cancers earlier and quicker, including NETs. In addition to the regular approaches above and the incidental findings which do help in early-stage diagnosis, those who are referred for conventional imaging have another chance of an early-stage diagnosis. It’s not true to say that undiagnosed NETs are never found on conventional imaging (scopes/xray/CT/MRI. I’m fairly confident if statistics existed most diagnoses are based on findings of conventional imaging. But add nuclear imaging which is advancing at a phenomenal rate compared to 10 years ago, the chances of finding NETs have been exponentially increased. The difficulty is getting to the stage of carrying out nuclear imaging, there can be several hurdles to jump not least the availability of PETs and nuclear radioligands.
I am seeing more and more early-stage NETs in my patient group in difficult to diagnose primary sites where many are diagnosed at a late stage meaning an incurable cancer with long term surveillance and reduced prognosis. e.g. Small Intestine NETs and Pancreatic NETs.

Most of the above can also be applied to Neuroendocrine Carcinomas (NECs), a poorly differentiated type of NEN, although different types of nuclear imaging might be needed.
Awareness is a game changer
Imaging cannot take all the credit though. More and more doctors (but still not enough) are becoming aware of NENs via foundation organisations such as NET Research Foundation, Neuroendocrine Cancer UK, Neuroendocrine Cancer Australia and the PheoPara Alliance (Pheochromocytoma/Paraganglioma). There are many more, but some remain fixated in other areas, hopefully they will catch up soon.
The awareness issue is also obfuscated by continued and unnecessary use of the term “carcinoid” including within the healthcare community. If they would just update themselves with the latest World Health Organisation (WHO) classification systems, they would realise how out of date they are. Ditto to any patient foundation organisation or patient group.
The other key fact coming out in 2023 is the continuation of a theme which has been improving since 2015, the fact that NENs are no longer rare. One major US cancer organisations underscored this awareness improvement earlier this year by very clearly stating that “NETs are uncommon but definitely not rare“. They also astonishingly went on to say the false perception that NET is a rare cancer has held back proper clinical research.
Worth pointing out that in UK and Australia, diligent and accurate cancer registry analysis put NENs as the 10th and 7th most prevalent cancers in those countries.
My own thinking is that if primary and secondary care doctors were all made aware of this fact, NETs might be something doctors would consider more rather than dismiss it as being a very unlikely diagnosis.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like this page.
I’m also active on this Facebook page. Follow this page.
Also like this awareness page on Facebook.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient

Summary of May 2023 on RonnyAllan.NET
Summary May produced the best statistics in 2023, mainly due to your support for my blog post on Maria Menounos whose announcement headlined as “Pancreatic

Getting back in the saddle
Those who follow my Facebook page Ronny Allan may remember my cycling faux pas in April causing me to bruise or fracture a rib (here

Clinical Trial: Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (incl Neuroendocrine Neoplasms)
Who are 23andMe? I personally had not heard of 23andMe but many people in North America might have. When you first look at what they

A spotlight on Chromogranin A
What is Chromogranin A? Chromogranin A (CgA) is an acidic protein released along with catecholamines from chromaffin cells and nerve terminals. This statement alone might

Neuroendocrine Cancer: Catch them early, not late!
Diagnosing Neuroendocrine Neoplasms (NENs). It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can

A spotlight on Rectal Neuroendocrine Neoplasms
What are Rectal NENs Rectal Neuroendocrine Neoplasms (NENs) (rNENs) account for approximately 1-2% of all primary cancers in the rectum. The other main cancer types

Clinical Trial: Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)
A new clinical trial post. What is Terbium-161 (161Tb-DOTA-LM3) (Beta plus). Terbium-161 is a radioactive substance. DOTA-LM3 is a novel somatostatin antagonist targeted using somatostatin

Repeat after me: Maria Menounos has Neuroendocrine Cancer
Like many people from outside USA, I don’t really know anything about Maria Menounos. For those in the same boat, let me confirm she is

Summary of April 2023 on RonnyAllan.NET
Summary of RonnyAllan.NET website activity in April 2023 The top 10 most read posts in April are included below as the main product of this summary
Subscribe to Blog via Email
A cup of tea

I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)